OncoMed
OncoMed initiates Phase Ib immuno-oncology combination clinical trial
March 18, 2016Medical Communications, Research and Development Merck, OncoMed, clinical trial, demcizumab, immuno-oncology, immuno-oncology combination, pembrolizumab, phase ib
OncoMed (NASDAQ: OMED) has announced the beginning of its Phase Ib clinical trial to investigate if the combination of demcizumab …
Celgene signs $177 million OncoMed deal
December 4, 2013Research and Development, Sales and Marketing Cancer, Celgene, OncoMed, stem cell
Celgene Corporation is paying OncoMed Pharmaceuticals $177.25 million to get access to its pipeline as part of a deal to …
Anti-cancer stem cell drug starts clinical trials
January 14, 2011Research and Development Cancer, GSK, GlaxoSmithKline, OMP-21M18, OMP-59R5, OncoMed, Stem cells, advanced solid tumour cancers
OncoMed and GSK’s novel anti cancer stem cell drug OMP-59R5 has begun clinical trials and could represent the future direction …
Bayer signs cancer stem cell research deal
June 18, 2010Research and Development Bayer Schering Pharma, Cancer, OncoMed, Stem cells
Bayer Schering Pharma has teamed up with a US oncology specialist to develop novel antibodies, protein therapeutics and small molecules …
Latest content
Pharma sees climate disruption as growing supply-chain risk
September 11, 2026
Manchester NHS-MHRA partnership to test new technologies in real-world care
September 10, 2026
